Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.
about
Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis.
P2860
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@ast
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@en
type
label
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@ast
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@en
prefLabel
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@ast
Tocilizumab in the treatment o ...... ectiveness analysis in the UK.
@en
P2093
P2860
P1433
P1476
Tocilizumab in the treatment o ...... fectiveness analysis in the UK
@en
P2093
Alex Diamantopoulos
D K Sungher
F Dejonckheere
T Huizinga
P2860
P2888
P304
P356
10.1007/S40273-014-0165-7
P50
P577
2014-08-01T00:00:00Z